claim: korean study of 25 000 people shows that current use of proton pump inhibitors may lead to 79 % greater risk of severe clinical outcomes of covid-19
evidence_1: using a large-scale, population-based, nationwide cohort in korea, we measured the potential associations of the current use of ppis with the infection rates of covid-19 among patients who underwent sars-cov-2 testing; we also assessed the influence of current ppi administrations to the disease severity of covid-19 in patients with laboratory-confirmed covid-19.